As the co-Founder, President, Chief Executive Officer, and Chairman of the Board of Seattle Genetics, Inc., Clay Siegall is at the forefront of cancer research. Seattle Genetics is a company, headquartered in Bothell, Washington, that creates cancer drugs using antibody-drug conjugates. Ever since the release of the drug Adcetris, which treats lymphoma and potentially other types of cancers, in 2012 the company’s stock has tripled in value.
Dr. Siegall has exhibited a passion throughout his career for helping patients that are suffering from cancer. He is a graduate of George Washington University where he earned his Ph.D. in Genetics. He began his professional career at Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator. He was promoted to Principal Scientist during his time at this institute. He has also performed research at the National Cancer Institute where he was a Staff Fellow and Biotechnology Fellow.
Helping cancer patients and diligently performing scientific research lies at the heart of Dr. Clay Siegall’s career. His cancer drug, Adcetris, is now being used in 60 countries and has helped saved many thousands of lives. He also has several more cancer drugs in the pipeline and is researching Adcetris’s promising potential to cure more types of cancer.
Due to Dr. Siegall’s leadership, Seattle Genetics has raised over $1.2 billion in funding from both the public and private sectors. This money has been used to hire more research staff, pay for more drug styles, and used to acquire the latest lab technology.
Dr. Siegall’s depth of knowledge and acumen has led to his acquiring 15 patents and having more than 70 scientific articles published.
As the leader of Seattle Genetics, Clay Siegall is responsible for the day-to-day operations of the company. He also is responsible for developing strategic partnerships with other companies. With Adcetris, Seattle Genetics markets and distributes it in the U.S. and Canada while Takeda Pharmaceutical Company does the same in the rest of the world. Dr. Siegall has also formed relationships with other companies such as Genentech, Pfizer, Abbvie, and GlaxoSmithKline.